玛巴洛沙韦治疗小儿流感的成本-效果分析

刘洋君; 唐宇忻; 王淑玲

doi:10.13748/j.cnki.issn1007-7693.20240660

玛巴洛沙韦治疗小儿流感的成本-效果分析

Cost-effectiveness Analysis of Baloxavir Marboxil in the Treatment of Pediatric Influenza

摘要

摘要:
目的评价玛巴洛沙韦治疗1~12岁小儿流感患者的经济性。
方法从中国卫生体系视角出发，基于1项玛巴洛沙韦Ⅲ期临床试验(NCT03629184)构建决策树模型，模拟玛巴洛沙韦和奥司他韦治疗小儿流感患者的治疗过程，研究时限为29 d。采用成本-效果分析计算增量成本-效果比(incremental cost-effectiveness ratio，ICER)，并通过旋风图、蒙特卡洛模拟进行敏感性分析。
结果基础分析结果显示，与奥司他韦相比，玛巴洛沙韦的增量效果是0.018，增量成本为85.71 元，ICER为4762.14 元，以2023年人均可支配收入(39218 元)作为基础分析的参考阈值，ICER为人均可支配收入的12.14%，属于优势方案。单因素分析结果显示玛巴洛沙韦和奥司他韦的成本影响较大，概率敏感性分析结果与基础分析一致。
结论与奥司他韦疗法相比，玛巴洛沙韦治疗1~12岁小儿流感患者的经济性更好。

Abstract:
OBJECTIVE To evaluate the economics of baloxavir marboxil in the treatment of pediatric influenza patients aged 1–12 years.
METHODS From the perspective of the Chinese health system, a decision tree model was constructed based on a phase Ⅲ clinical trial of baloxavir marboxil(NCT03629184) to simulate the treatment process of baloxavir marboxil and oseltamivir in pediatric influenza patients. The study time was 29 d. The incremental cost-effectiveness ratio(ICER) was calculated by cost-effectiveness analysis, and the sensitivity was analyzed by cyclone map and Monte Carlo simulation.
RESULTS The results of basic analysis showed that compared with oseltamivir, the incremental effect of baloxavir marboxil was 0.018, the incremental cost was 85.71 yuan, and ICER was 4762.14 yuan. Taking the per capita disposable income in 2023(39218 yuan) as the reference threshold for basic analysis, ICER was 12.14% of the per capita disposable income. It belonged to the advantageous scheme. The results of single factor analysis showed that the cost of baloxavir marboxil and oseltamivir was significantly affected, and the results of probabilistic sensitivity analysis were consistent with the basic analysis.
CONCLUSION Compared with oseltamivir therapy, baloxavir marboxil is more economical in the treatment of pediatric influenza patients aged 1–12 years.

HTML全文

参考文献(18)

施引文献

资源附件(0)